杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2023/01/24 | 1,694 | 1,714 | 1,692 | 1,710 | +16 | +0.9% | 53,700 |
| 2023/01/23 | 1,697 | 1,710 | 1,692 | 1,694 | +5 | +0.3% | 48,400 |
| 2023/01/20 | 1,689 | 1,694 | 1,681 | 1,689 | +5 | +0.3% | 31,000 |
| 2023/01/19 | 1,679 | 1,686 | 1,669 | 1,684 | +8 | +0.5% | 47,200 |
| 2023/01/18 | 1,654 | 1,683 | 1,653 | 1,676 | +29 | +1.8% | 36,100 |
| 2023/01/17 | 1,654 | 1,658 | 1,644 | 1,647 | -7 | -0.4% | 43,800 |
| 2023/01/16 | 1,639 | 1,666 | 1,639 | 1,654 | +8 | +0.5% | 40,300 |
| 2023/01/13 | 1,655 | 1,664 | 1,643 | 1,646 | -15 | -0.9% | 68,000 |
| 2023/01/12 | 1,663 | 1,665 | 1,655 | 1,661 | +4 | +0.2% | 37,700 |
| 2023/01/11 | 1,649 | 1,664 | 1,649 | 1,657 | +12 | +0.7% | 40,600 |
| 2023/01/10 | 1,663 | 1,675 | 1,645 | 1,645 | -18 | -1.1% | 80,300 |
| 2023/01/06 | 1,682 | 1,682 | 1,662 | 1,663 | -8 | -0.5% | 60,500 |
| 2023/01/05 | 1,680 | 1,680 | 1,667 | 1,671 | -12 | -0.7% | 72,100 |
| 2023/01/04 | 1,712 | 1,713 | 1,683 | 1,683 | -37 | -2.2% | 65,400 |
| 2022/12/30 | 1,720 | 1,733 | 1,719 | 1,720 | -3 | -0.2% | 27,700 |
| 2022/12/29 | 1,700 | 1,726 | 1,699 | 1,723 | +16 | +0.9% | 68,800 |
| 2022/12/28 | 1,704 | 1,708 | 1,701 | 1,707 | -1 | -0.1% | 36,800 |
| 2022/12/27 | 1,712 | 1,721 | 1,705 | 1,708 | -3 | -0.2% | 29,800 |
| 2022/12/26 | 1,716 | 1,717 | 1,706 | 1,711 | -8 | -0.5% | 24,300 |
| 2022/12/23 | 1,724 | 1,731 | 1,714 | 1,719 | +1 | +0.1% | 60,300 |
| 2022/12/22 | 1,702 | 1,720 | 1,700 | 1,718 | +7 | +0.4% | 41,400 |
| 2022/12/21 | 1,712 | 1,721 | 1,696 | 1,711 | -8 | -0.5% | 81,000 |
| 2022/12/20 | 1,737 | 1,742 | 1,707 | 1,719 | -13 | -0.8% | 76,100 |
| 2022/12/19 | 1,714 | 1,738 | 1,714 | 1,732 | +17 | +1% | 40,000 |
| 2022/12/16 | 1,735 | 1,744 | 1,715 | 1,715 | -31 | -1.8% | 170,400 |
| 2022/12/15 | 1,759 | 1,761 | 1,746 | 1,746 | -13 | -0.7% | 51,600 |
| 2022/12/14 | 1,755 | 1,771 | 1,750 | 1,759 | +12 | +0.7% | 89,300 |
| 2022/12/13 | 1,743 | 1,750 | 1,734 | 1,747 | +18 | +1% | 67,800 |
| 2022/12/12 | 1,736 | 1,739 | 1,725 | 1,729 | -17 | -1% | 40,400 |
| 2022/12/09 | 1,746 | 1,749 | 1,725 | 1,746 | +3 | +0.2% | 144,100 |
| 2022/12/08 | 1,751 | 1,754 | 1,723 | 1,743 | -5 | -0.3% | 89,500 |
| 2022/12/07 | 1,720 | 1,754 | 1,718 | 1,748 | +20 | +1.2% | 87,500 |
| 2022/12/06 | 1,717 | 1,736 | 1,717 | 1,728 | -5 | -0.3% | 76,500 |
| 2022/12/05 | 1,740 | 1,740 | 1,717 | 1,733 | -13 | -0.7% | 80,300 |
| 2022/12/02 | 1,752 | 1,761 | 1,729 | 1,746 | -21 | -1.2% | 92,100 |
| 2022/12/01 | 1,782 | 1,782 | 1,754 | 1,767 | -3 | -0.2% | 60,900 |
| 2022/11/30 | 1,776 | 1,792 | 1,767 | 1,770 | -28 | -1.6% | 97,700 |
| 2022/11/29 | 1,830 | 1,830 | 1,793 | 1,798 | -46 | -2.5% | 84,700 |
| 2022/11/28 | 1,873 | 1,873 | 1,837 | 1,844 | -35 | -1.9% | 62,100 |
| 2022/11/25 | 1,879 | 1,883 | 1,862 | 1,879 | +17 | +0.9% | 64,800 |
| 2022/11/24 | 1,846 | 1,868 | 1,841 | 1,862 | -5 | -0.3% | 102,700 |
| 2022/11/22 | 1,850 | 1,869 | 1,850 | 1,867 | +25 | +1.4% | 83,300 |
| 2022/11/21 | 1,837 | 1,846 | 1,832 | 1,842 | +5 | +0.3% | 46,300 |
| 2022/11/18 | 1,823 | 1,840 | 1,793 | 1,837 | +32 | +1.8% | 69,300 |
| 2022/11/17 | 1,780 | 1,805 | 1,780 | 1,805 | +29 | +1.6% | 47,700 |
| 2022/11/16 | 1,779 | 1,789 | 1,774 | 1,776 | +1 | +0.1% | 37,800 |
| 2022/11/15 | 1,770 | 1,793 | 1,762 | 1,775 | +13 | +0.7% | 54,700 |
| 2022/11/14 | 1,771 | 1,775 | 1,755 | 1,762 | -9 | -0.5% | 39,000 |
| 2022/11/11 | 1,782 | 1,789 | 1,754 | 1,771 | +29 | +1.7% | 108,400 |
| 2022/11/10 | 1,738 | 1,743 | 1,712 | 1,742 | -44 | -2.5% | 189,600 |
451～
500
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,500円 | +3.2% | +4.5% | 3.48% | 17.18倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 223,200円 | +13.6% | +29.2% | 2.06% | 11.58倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,800円 | +197.7% | - | 0.00% | 46.51倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 72,000円 | -3.7% | -36.7% | 2.78% | 23.71倍 | 1.55倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 211,100円 | +0.4% | -8.4% | 2.51% | 27.90倍 | 1.59倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
